Review
Oncology
Khalid I. Bzeizi, Mohammad Arabi, Negar Jamshidi, Ali Albenmousa, Faisal M. Sanai, Waleed Al-Hamoudi, Saad Alghamdi, Dieter Broering, Saleh A. Alqahtani
Summary: DEB-TACE treatment shows better objective response, disease control, and lower all-cause mortality with fewer severe complications compared to C-TACE, while not demonstrating clear superiority in complete or partial response, disease stability, or controlling disease progression.
Article
Radiology, Nuclear Medicine & Medical Imaging
Sihang Cheng, Ge Hu, Zhengyu Jin, Zhiwei Wang, Huadan Xue
Summary: This study developed and validated a CT-based radiomics model to predict the overall survival (OS) of HCC patients with PVTT treated with DEB-TACE. It was found that the type of PVTT and tumor number were significant indicators for OS. The combined clinical-radiomics model showed satisfactory performance in predicting 12-month OS.
EUROPEAN RADIOLOGY
(2023)
Article
Medicine, General & Internal
Zi-Yu Wang, Chun-Feng Xie, Kun-Liang Feng, Cheng-Ming Xiong, Jun-Hai Huang, Qing-Lian Chen, Chong Zhong, Zhai-Wen Zhou
Summary: DEB-TACE shows significantly improved objective tumor response rate compared to cTACE, but is similar to cTACE in terms of overall survival and adverse events rate, indicating that it is not superior to cTACE.
Article
Oncology
Kun Ji, Hanlong Zhu, Wei Wu, Xin Li, Pengchao Zhan, Yang Shi, Junhui Sun, Zhen Li
Summary: The study aims to explore the tumor response and propose a nomogram-based prognostic stratification for HCC after DEB-TACE. A total of 335 patients were included in the study. The nomogram demonstrated good calibration and discrimination, outperforming other staging systems. The prognostic stratification classified patients into three different risk groups, which showed significant differences in survival and tumor response rates.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2022)
Article
Oncology
Weihua Zhang, Lei Chen, Yanyan Cao, Bo Sun, Yanqiao Ren, Tao Sun, Chuansheng Zheng
Summary: The study found that treating unresectable HCC patients with D-TACE-A did not result in improved survival compared to C-TACE-A. However, in specific subgroups, D-TACE-A showed lower risks in certain aspects. Different patients may benefit from different treatment strategies.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Chenghao Zhao, Huzheng Yan, Zhanwang Xiang, Haofan Wang, Mingan Li, Mingsheng Huang
Summary: The study compared the effectiveness and safety of IDA-TACE and EPI-TACE in treating hepatocellular carcinoma. IDA-TACE was found to be more effective than EPI-TACE for advanced-stage HCC and comparable for intermediate-stage HCC.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Multidisciplinary Sciences
William T. N. Culp, Eric G. Johnson, Michelle A. Giuffrida, Robert B. Rebhun, James K. Cawthra, Heidi A. Schwanz, Jenna H. Burton, Michael S. Kent
Summary: This study describes the use of a novel drug-eluting microsphere in transarterial chemoembolization for dogs with non-resectable hepatic neoplasia. The results show significant reduction in tumor volume and improvement in clinical signs.
Article
Medicine, General & Internal
Kazue Shiozawa, Takashi Matsui, Takahiro Murakami, Manabu Watanabe, Iruru Maetani
Summary: The study aimed to evaluate the utility of contrast-enhanced ultrasound (CEUS) in predicting therapeutic efficacy of transarterial chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). CEUS performed within 3 days after DEB-TACE may allow early assessment of therapeutic efficacy, with findings of no enhancement or peripheral ring enhancement suggesting a positive outcome.
Article
Oncology
Wenzhe Fan, Bowen Zhu, Xinlin Zheng, Shufan Yue, Mingjian Lu, Huishuang Fan, Liangliang Qiao, Fuliang Li, Guosheng Yuan, Yanqin Wu, Xinhua Zou, Hongyu Wang, Miao Xue, Jiaping Li
Summary: This study investigated the effectiveness and safety of combining sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of early intrahepatic stage-progressed advanced hepatocellular carcinoma (ISPA-HCC). The results showed that the combination therapy significantly improved tumor response rates, overall survival, and time to progression compared to sorafenib monotherapy. However, the DTS group had a higher incidence of adverse events during treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Dongdong Xia, Wei Bai, Enxin Wang, Jiaping Li, Xiaoming Chen, Zhexuan Wang, Mingsheng Huang, Ming Huang, Junhui Sun, Weizhu Yang, Zhengyu Lin, Jianbing Wu, Zixiang Li, Shufa Yang, Xu Zhu, Zaizhong Chen, Yanfang Zhang, Wenzhe Fan, Qicong Mai, Rong Ding, Chunhui Nie, Long Feng, Xueda Li, Wukui Huang, Jun Sun, Qiuhe Wang, Yong Lv, Xiaomei Li, Bohan Luo, Zhengyu Wang, Jie Yuan, Wengang Guo, Kai Li, Bing Li, Ruijun Li, Zhanxin Yin, Jielai Xia, Guohong Han
Summary: This study compared the clinical outcomes of lenvatinib plus DEB-TACE versus lenvatinib alone in treating HCC, demonstrating that the combination therapy was more effective in improving overall survival, progression-free survival, and objective response rate. Adverse events were mostly mild-to-moderate in both groups.
Review
Pharmacology & Pharmacy
Roshana Saghafian Larijani, Nazanin Shabani Ravari, Navid Goodarzi, Shahram Akhlaghpour, Samaneh Saghafian Larijani, Mohammad Reza Rouini, Rassoul Dinarvand
Summary: Primary liver cancer is the fourth most common cause of cancer-related mortality worldwide, with hepatocellular carcinoma being the most prevalent histological type. Among various therapeutic options, transarterial chemoembolization is an efficient option for patients with intermediate stage HCC. Different embolic materials used in the TACE procedure have their own pros and cons.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Oncology
Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-Hsiang Huang, Jia- Liao, Chien-Wei Su, Ming-Chih Hou, Teh-Ia Huo
Summary: Tumor burden score (TBS), estimated by the diameter and number of tumor nodules, is a feasible prognostic marker for HCC patients within the Milan criteria. Among patients with low TBS, radiofrequency ablation (RFA) should be considered the priority treatment modality.
Article
Oncology
Yanqiao Ren, Yusheng Guo, Lei Chen, Tao Sun, Weihua Zhang, Bo Sun, Licheng Zhu, Fu Xiong, Chuansheng Zheng
Summary: This study compared the efficacy and safety of D-TACE-C and C-TACE-C in the treatment of unresectable HCC. The results showed that D-TACE-C group had significantly longer PFS and higher DCR compared to the C-TACE-C group. D-TACE-C is a safe and well-tolerated treatment that may produce better PFS and tumor response in patients with unresectable HCC.
Article
Health Care Sciences & Services
Evgenia Kotsifa, Chrysovalantis Vergadis, Michael Vailas, Nikolaos Machairas, Stylianos Kykalos, Christos Damaskos, Nikolaos Garmpis, Georgios D. Lianos, Dimitrios Schizas
Summary: HCC is the most common primary liver malignancy associated with liver cirrhosis and chronic liver disease. Key risk factors for HCC development include viral infections, alcoholic liver disease, and nonalcoholic fatty liver disease. Treatment options for HCC depend on tumor burden, liver function, and patient's health status, with surgical resection, transplantation, ablation, TACE, and systemic therapy being potential strategies.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Liang Cai, Honglu Li, Jiang Guo, Wenpeng Zhao, Youquan Li, Youjia Duan, Xiaopu Hou, Long Cheng, Hongliu Du, Xihong Shao, Zhenying Diao, Yiwei Hao, Changqing Li
Summary: DEB-TACE plus MWA shows promising efficacy and comparable survival profiles to surgery in treating patients with HCC adjacent to the gallbladder, with a higher intraoperative adverse event incidence but no difference in postoperative adverse events compared to surgery.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Article
Oncology
Kyunghye Bang, Andrea Casadei-Gardini, Changhoon Yoo, Massimo Iavarone, Min-Hee Ryu, Sook Ryun Park, Hyung-Don Kim, Young-In Yoon, Dong-Hwan Jung, Gil-Chun Park, Chul-Soo Ahn, Deok-Bog Moon, Shin Hwang, Ki-Hun Kim, Gi-Won Song, Chiara Mazzarelli, Eleonora Alimenti, Stephen L. Chan, Massimo De Giorgio, Baek-Yeol Ryoo, Sung-Gyu Lee
Summary: This study investigated the efficacy and safety of lenvatinib in patients with post-liver transplantation (LT) hepatocellular carcinoma (HCC) recurrence. The results showed consistent efficacy and toxicity profiles of lenvatinib in these patients, comparable to previous studies on non-LT HCC patients. In addition, the baseline ALBI grade was associated with improved overall survival in post-LT lenvatinib-treated patients.
Article
Gastroenterology & Hepatology
Massimo Iavarone, Giulia Tosetti, Floriana Facchetti, Matilde Topa, Joey Ming Er, Shou Kit Hang, Debora Licari, Andrea Lombardi, Roberta D'Ambrosio, Elisabetta Degasperi, Alessandro Loglio, Chiara Oggioni, Riccardo Perbellini, Riccardo Caccia, Alessandra Bandera, Andrea Gori, Ferruccio Ceriotti, Luigia Scudeller, Antonio Bertoletti, Pietro Lampertico
Summary: This study found that patients with cirrhosis have a suboptimal immune response to COVID-19 vaccines, particularly in those who have not been infected with SARS-CoV-2 before. However, the cellular immune response in patients with cirrhosis remains preserved, and a low rate of breakthrough infections was observed.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Immunology
Francesco Tovoli, Dante Pio Pallotta, Vito Sansone, Massimo Iavarone, Massimo De Giorgio, Luca Ielasi, Giovan Giuseppe Di Costanzo, Paolo Giuffrida, Rodolfo Sacco, Tiziana Pressiani, Maria Francesca Di Donato, Franco Trevisani, Stefano Fagiuoli, Fabio Piscaglia, Alessandro Granito
Summary: This study retrospectively analyzed the characteristics and outcomes of sorafenib-treated HCC patients in a large multicenter dataset, showing that multimodal and sequential treatments are relatively frequent in post-LT HCC patients and contribute to a remarkable overall survival, together with favorable baseline characteristics.
Article
Oncology
Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti
Summary: This retrospective multi-center study compared the clinical efficacy and safety of lenvatinib and atezolizumab plus bevacizumab as a first-line treatment for unresectable HCC. The results showed that atezolizumab plus bevacizumab did not have a significant survival advantage over lenvatinib overall. However, lenvatinib had a higher overall survival rate in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, while atezolizumab plus bevacizumab had a higher overall survival rate in patients with viral hepatitis. After adjusting for population, atezolizumab plus bevacizumab provided better safety profile for most adverse events.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study compares the response rates of lenvatinib and atezolizumab plus bevacizumab in the first-line treatment of hepatocellular carcinoma (HCC) patients. The results show that lenvatinib achieves higher response rates in all patient subgroups. Patients who achieve complete response with atezolizumab plus bevacizumab can achieve a better overall survival compared to other treatments.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Alessio Aghemo, Marcello Persico, Roberta D'Ambrosio, Massimo Andreoni, Erica Villa, Abhi Bhagat, Valentina Gallinaro, Giuliana Gualberti, Rocco Cosimo Damiano Merolla, Antonio Gasbarrini
Summary: A study conducted in Italy found that G/P treatment achieved a 100% cure rate in patients with hepatitis C, even in high-risk groups such as elderly patients and those with advanced liver disease.
Review
Gastroenterology & Hepatology
Nicola Pugliese, Ludovico Alfarone, Ivan Arcari, Silvia Giugliano, Tommaso Lorenzo Parigi, Maria Rescigno, Ana Lleo, Alessio Aghemo
Summary: Nonalcoholic fatty liver disease (NAFLD) is replacing viral hepatitis as the leading cause of chronic liver disease and hepatocellular carcinoma (HCC) in many Western countries. NAFLD-associated HCC usually affects older patients with multiple comorbidities, frequently develops in the absence of cirrhosis, and is often diagnosed later with worse chance of survival. The worse prognosis is also due to limited surveillance strategies and a lower efficacy of standard treatments.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Medicine, General & Internal
Niccolo Bitto, Gabriele Ghigliazza, Stanislao Lavorato, Camilla Caputo, Vincenzo La Mura
Summary: Portal hypertension is a consequence of cirrhosis, which is characterized by increased sinusoidal vascular resistance and hepatic blood inflow. In addition to etiological therapies, other pathophysiological factors such as inflammation, bacterial translocation, endothelial dysfunction, and hyperactivation of hemostasis can worsen liver disease. Drugs such as albumin, rifaximin, statins, aspirin, and anticoagulants have been tested as non-etiological therapies in cirrhosis and may offer potential benefits based on their ability to target these mechanisms. This review provides a summary of the main mechanisms targeted by these drugs and the clinical evidence supporting their use as a complementary option for managing cirrhosis and portal hypertension.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Maria Paola Anolli, Elisabetta Degasperi, Lena Allweiss, Angelo Sangiovanni, Marco Maggioni, Caroline Scholtes, Valerie Oberhardt, Christoph Neumann-Haefelin, Maura Dandri, Fabien Zoulim, Pietro Lampertico
Summary: Bulevirtide has received conditional approval from the EMA for treating chronic hepatitis delta, but the optimal duration of therapy remains unknown. In this study, a patient with compensated cirrhosis and esophageal varices achieved hepatitis delta cure after 3 years of bulevirtide monotherapy. Virological and biochemical responses were maintained during the 72-week off-therapy follow-up, and significant improvements were observed in liver biopsy results.
JOURNAL OF HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Laura Turco, Thomas Reiberger, Giovanni Vitale, Vincenzo La Mura
Summary: Portal hypertension is a common complication of cirrhosis and plays a crucial role in hepatic decompensation. Carvedilol, a non-selective beta-blocker, has shown superior efficacy in reducing portal hypertension compared to traditional beta-blockers, making it a preferred treatment option for clinically significant portal hypertension in patients with cirrhosis.
LIVER INTERNATIONAL
(2023)
Article
Oncology
Catia Giovannini, Fabrizia Suzzi, Francesco Tovoli, Mariangela Bruccoleri, Mariarosaria Marseglia, Eleonora Alimenti, Francesca Fornari, Massimo Iavarone, Fabio Piscaglia, Laura Gramantieri
Summary: By using a simple cytofluorimetric test on peripheral blood, we discovered that patients with a low baseline PD1+ granulocyte percentage are more likely to benefit from atezolizumab-bevacizumab treatment. These findings need to be validated in larger cohorts to determine the potential use of this test in clinical practice.
Editorial Material
Oncology
Andrea Nicolini
Editorial Material
Gastroenterology & Hepatology
Julia Fischer, Vincenzo La Mura, Jonel Trebicka
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Filippo Pelizzaro, Franco Trevisani, Vittorio Simeon, Alessandro Vitale, Umberto Cillo, Fabio Piscaglia, Gabriele Missale, Angelo Sangiovanni, Francesco G. Foschi, Giuseppe Cabibbo, Eugenio Caturelli, Maria Di Marco, Francesco Azzaroli, Maurizia R. Brunetto, Giovanni Raimondo, Gianpaolo Vidili, Maria Guarino, Antonio Gasbarrini, Claudia Campani, Gianluca Svegliati-Baroni, Edoardo G. Giannini, Andrea Mega, Alberto Masotto, Gian Ludovico Rapaccini, Donatella Magalotti, Rodolfo Sacco, Gerardo Nardone, Fabio Farinati
Summary: This study evaluated the incidence and predictors of non-transplantable recurrence in patients with single hepatocellular carcinoma (HCC) <= 5 cm treated with liver resection (LR). The results showed that HCC size >= 4 cm and high alpha-fetoprotein (AFP) level at the time of LR were independent predictors of recurrence beyond established criteria. Microvascular invasion and microsatellite lesions were identified as additional independent risk factors for non-transplantable recurrence.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Pierre Deltenre, Audrey Payance, Laure Elkrief, Vincenzo La Mura, Florent Artru, Anna Baiges, Jean-Paul Cervoni, Louise China, Isabelle Colle, Elise Lemaitre, Dietmar Schiller, Christophe Bureau, Odile Goria, Isabelle Ollivier, Alexandre Nuzzo, Pierre-Emmanuel Rautou, Aurelie Plessier, VALDIG EASL consortium
Summary: SARS-CoV-2 infection may be associated with recent SVT. Patients with SARS-CoV-2 infection have a higher frequency of respiratory symptoms and a lower lymphocyte count. Intestinal infarction leading to intestinal resection appears to occur more frequently in patients with SARS-CoV-2.